Molecular Formula | C22H20F2N4O2 |
Molar Mass | 410.4166 |
Density | 1.347±0.06 g/cm3(Predicted) |
Melting Point | 173 - 175°C |
Boling Point | 596.1±50.0 °C(Predicted) |
Solubility | DMSO: ≥ 30 mg/mL |
Appearance | Form Solid, color White to Off-White |
pKa | 12.30±0.40(Predicted) |
Storage Condition | -20°C, Inert atmosphere |
Use | The lemborexant of use is a dual inhibitor of OX1 and OX2 receptors, discovered and developed by Eisai. The compound inhibits orexin by competitively binding to 2 subtypes of orexin receptors (orexin receptor 1 and receptor 2). |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.437 ml | 12.183 ml | 24.365 ml |
5 mM | 0.487 ml | 2.437 ml | 4.873 ml |
10 mM | 0.244 ml | 1.218 ml | 2.437 ml |
5 mM | 0.049 ml | 0.244 ml | 0.487 ml |
solubility | DMSO (Slightly), Methanol (Slightly) |
lemborexant interfere with orexin neurotransmission and purposeful promotion of sleep initiation and maintenance. At present, Aisai is cooperating with Purdue to develop lemborexant for the treatment of various sleep disorders.